Kolon TissueGene, Inc. Logo

Kolon TissueGene, Inc.

Developing cell and gene therapies for orthopedic and degenerative disorders.

950160 | KO

Overview

Corporate Details

ISIN(s):
KR8840120008
LEI:
Country:
United States of America
Address:
9713 Key West Ave Suite 300, Rockville
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, disease-modifying allogeneic cell therapy for the treatment of knee osteoarthritis. This innovative therapy is designed to reduce pain, improve joint function, and potentially slow disease progression. Kolon TissueGene is advancing TG-C through late-stage clinical trials and exploring the application of its platform technology for other degenerative conditions, such as spinal diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 88.5 KB
2025-09-11 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.0 KB
2025-09-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 13.9 KB
2025-09-09 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 19.1 KB
2025-09-04 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.6 KB
2025-08-27 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.7 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 7.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-28 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 13.1 KB
2025-07-24 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.3 KB
2025-07-22 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 16.7 KB
2025-07-14 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (기술수출 계약 체결(당사의 라이센시인 코오롱생명과학㈜ 주요경영사항))
Korean 17.9 KB
2025-07-11 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사 (제2회차)
Korean 11.8 KB
2025-07-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 16.2 KB
2025-07-10 00:00
Share Issue/Capital Change
전환청구권행사 (제2회차)
Korean 8.7 KB

Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kolon TissueGene, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden
ERMA
Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.